XBIO

Xenetic Biosciences Inc

XBIO, USA

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

https://www.xeneticbio.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
XBIO
stock
XBIO

Retail Surge: Will AeroVironment Inc stock see insider buying - July 2025 Action & AI Forecast for Swing Trade Picks moha.gov.vn

Read more →
XBIO
stock
XBIO

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting The Herald-Mail

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$40

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.95

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-12.89 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.06 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-64.10 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.28

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 4.86% of the total shares of Xenetic Biosciences Inc

1.

Renaissance Technologies Corp

(1.6049%)

since

2025/06/30

2.

Sachetta LLC

(0.9895%)

since

2025/06/30

3.

Geode Capital Management, LLC

(0.6794%)

since

2025/06/30

4.

Fidelity Extended Market Index

(0.4401%)

since

2025/07/31

5.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4365%)

since

2025/07/31

6.

JTC Employer Solutions Trustee Ltd

(0.1751%)

since

2025/06/30

7.

Fidelity Nasdaq Composite Index

(0.1342%)

since

2025/07/31

8.

Fidelity Series Total Market Index

(0.09%)

since

2025/07/31

9.

NT Ext Equity Mkt Idx Fd - NL

(0.0659%)

since

2025/06/30

10.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0512%)

since

2025/06/30

11.

Northern Trust Extended Eq Market Idx

(0.0493%)

since

2025/06/30

12.

NT Ext Equity Mkt Idx Fd - L

(0.0493%)

since

2025/06/30

13.

State St US Extended Mkt Indx NL Cl C

(0.0253%)

since

2025/08/31

14.

Spartan Total Market Index Pool G

(0.0241%)

since

2025/07/31

15.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0139%)

since

2025/06/30

16.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0117%)

since

2024/12/31

17.

SSgA U.S. Total Market Index Strategy

(0.0106%)

since

2025/03/31

18.

Spartan Extended Market Index Pool F

(0.0031%)

since

2025/07/31

19.

Fidelity U.S. Equity Index Ins Trust

(0.0012%)

since

2025/07/31

20.

Bank of America Corp

(0.0008%)

since

2025/06/30

21.

SBI Securities Co Ltd

(0.0003%)

since

2025/06/30

22.

Morgan Stanley - Brokerage Accounts

(0.0003%)

since

2025/06/30

23.

Harwood Advisory Group, LLC

(0.0001%)

since

2025/06/30

25.

Barclays PLC

(0%)

since

2025/06/30

26.

Citadel Advisors Llc

(0%)

since

2025/06/30

27.

UBS Group AG

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.33

EPS Estimate

-0.84

EPS Difference

0.51

Surprise Percent

60.7143%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Fair GARP(4.5)
Growth
Weak Growth Prospect(3)
Momentum
No Momentum(3)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(3)
Value
Undervalued(7)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.